Thyroid Cancer: A Comprehensive Guide to Clinical Management
Editat de Leonard Wartofsky, Douglas Van Nostranden Limba Engleză Hardback – 20 sep 2016
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (2) | 1127.96 lei 38-44 zile | |
Springer – 9 iun 2018 | 1127.96 lei 38-44 zile | |
Humana Press Inc. – 17 sep 2011 | 2210.25 lei 6-8 săpt. | |
Hardback (2) | 1613.81 lei 38-44 zile | |
Springer – 20 sep 2016 | 1613.81 lei 38-44 zile | |
Humana Press Inc. – 14 noi 2005 | 1804.78 lei 38-44 zile |
Preț: 1613.81 lei
Preț vechi: 1698.74 lei
-5% Nou
Puncte Express: 2421
Preț estimativ în valută:
308.85€ • 319.71$ • 261.04£
308.85€ • 319.71$ • 261.04£
Carte tipărită la comandă
Livrare economică 01-07 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781493933129
ISBN-10: 1493933124
Pagini: 943
Ilustrații: XXXI, 1049 p. 271 illus., 81 illus. in color.
Dimensiuni: 210 x 279 x 56 mm
Greutate: 3.52 kg
Ediția:3rd ed. 2016
Editura: Springer
Colecția Springer
Locul publicării:New York, NY, United States
ISBN-10: 1493933124
Pagini: 943
Ilustrații: XXXI, 1049 p. 271 illus., 81 illus. in color.
Dimensiuni: 210 x 279 x 56 mm
Greutate: 3.52 kg
Ediția:3rd ed. 2016
Editura: Springer
Colecția Springer
Locul publicării:New York, NY, United States
Public țintă
Professional/practitionerCuprins
PART I. General Considerations I: THYROID CANCER.- 1 Anatomy and Physiology of the thyroid gland: Clinical Correlates to Thyroid Cancer.- 2 Epidemiology of Thyroid Cancer.- 3 Molecular Pathogenesis of Thyroid Cancer & Oncogenes in Thyroid Cancer.- 4 Molecular Aspects of Thyroid Cancer in Children.- 5 The Role of Genetics in the Development of Familial Non-Medullary Thyroid Cancer.- 6 Apoptosis in Thyroid Cancer.- 7 Radiation-Induced Thyroid Cancer.- 8 Classification of Thyroid Malignancies.- 9 Staging of Thyroid Cancer.- 10 Recombinant human Thyrotropin (Thyrogen®).- PART II. GENERAL CONSIDERATIONS II: NUCLEAR MEDICINE.- 11 Radioiodine Whole Body Imaging.- 12 Primer and Atlas for the Interpretation of Radioiodine Whole-Body Scintigraphy.- 13 False-Positive Radioiodine-131 scans in Thyroid Cancer.- 14 The Utility of SPECT-CT in Differentiated Thyroid Cancer.- 15 Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for staging and risk stratification.- 16 Stunning by 131I scanning: Untoward Effect of 131I Thyroid Imaging Prior to Radioablation Therapy.- 17 Stunning is Not a Problem.- 18 Stunning: Does it Exist? A Commentary.- 19 To Perform or Not to Perform Radioiodine Scans Prior to 131I Remnant Ablation?.- PART III. THE THYROID NODULE.- 20 The Thyroid Nodule: Evaluation, Risk of Malignancy, and Management.- 21 Fine-Needle Aspiration.- 22 Diagnostic and Prognostic Molecular Markers in Thyroid Cancer.- 23 Ultrasonic Imaging of the Thyroid Gland.- 24 Radionuclide Imaging of Thyroid Nodules.- 25 18F Fluoro-deoxyglucose PET and Thyroid Nodules.- 26 Thyroid Nodules and Cancer Risk: Surgical Management.- 27 Thyroid Nodules in Children and Cancer Risk.- 28 Management of the Thyroid Nodule: A Comparison Of Published International Guidelines.- PART IV. WELL-DIFFERENTIATED THYROID CANCER A: PAPILLARY CARCINOMA: PRESENTATION.- 29 Papillary Carcinoma: Clinical Aspects.- 30 Papillary Microcarcinoma.- 31 Surgical Approach to Papillary Thyroid Cancer.- 32 Papillary Carcinoma: Cytology and Pathology.- B. INITIAL MANAGEMENT.- 33 Remnant Ablation, Adjuvant Treatment and Treatment of Locoregional Metastases with 131I.- 34 Thyroid Remnant Radioiodine Ablation with Recombinant Human Thyrotropin.- C. SURVEILLANCE.- 35 Follow-up Strategy in Papillary Thyroid Cancer.- 36 Thyroid Hormone Therapy and Thyrotropin Suppression.- 37 Thyroglobulin for Differentiated Thyroid Cancer: Measurement and Interferences.- 38 Thyroglobulin Antibodies and Their Measurement.- 39 Diagnosis of Recurrent Thyroid Cancer in Patients with Anti-Thyroglobulin Antibodies.- 40 Ultrasound of the neck lymph nodes.- 41 Surveillance Radioiodine Whole Body Scans.- 42 Radionuclide Imaging and Treatment of Children with Thyroid Cancer.- 43 Positron Emission Tomography-/Computed Tomography (PET-CT and PET) in Well-Differentiated Thyroid Cancer.- 44 Alternative Thyroid Imaging.- 45 MR and CT Imaging of Thyroid Cancer.- 46 Thyroglobulin in Lymph Node Aspirate.- 47 Management of the Patientswith Negative Radioiodine Scan and Elevated Serum Thyroglobulin.- 48 Prognosis in Papillary Thyroid Cancer.- 49 Surgical Management of Lymph Node Metastases.- 50 Utility of Second Surgery for Lymph Node Metastases.- 51 Papillary Cancer Special Aspects in Children.- 52 Special Presentations of Thyroid Cancer in Thyrotoxicosis, Renal Failure, and Struma Ovarii.- 53 Thyroglossal Duct Carcinoma.- 54 Thyroid Cancer in Pregnancy.- D. TREATMENT.- 55 Radiation and Radioactivity.- 56 131I Treatment of Distant Metastases.- 57 Treatment of Metastatic Thyroid Cancer with Radioiodine following preparation by Recombinant Human Thyrotopin.- 58 Dosimetrically-Determined Prescribed Activity of 131I for the Treatment of Metastatic Differentiated Thyroid Carcinoma.- 59 Simplified Methods of Dosimetry.- 60 Radioiodine Dosimetry with Recombinant human Thyrotropin.- 61 The Use of Lithium as an Adjuvant to Radioiodine In the Treatment of Thyroid Cancer.- 62 Side Effects of 131I for Therapy of DifferentiatedThyroid Carcinoma.- 63 Radiation Therapy in Papillary Carcinoma.- 64 Chemotherapy of Thyroid Cancer: General Principles.- 65 Bone Metastases from Differentiated Thyroid Carcinoma.- 66 A Summary of Rare Sites of Metastasis Secondary to Differentiated Thyroid Cancer.- 67 Adjunctive Local Approaches to Thyroid Nodules and Metastatic Thyroid Cancer.- 68 Radioiodine-Refractory Thyroid Cancer: Restoring Response to Radioiodine Therapy.- 69 Alternative and Complementary Treatment of Thyroid Disorders.- PART V. WELL-DIFFERENTIATED THYROID CANCER FOLLICULAR CARCINOMA.- 70 Follicular Thyroid Carcinoma.- 71 Surgical Management of Follicular Cancer.- 72 Pathology of Follicular Cancer.- 73 Hürthle Cell Carcinoma.- 74 Follow-Up Strategy in Follicular Thyroid Cancer.- 75 Radionuclide Imaging and 131I Therapy in Follicular Thyroid Carcinoma.- 76 PET/CT in Follicular Cancer Including Hürthle Cell Cancer.- 77 Follicular Thyroid Cancer: Special Aspects in Children and Adolescents.- 78 External Radiation Therapy of Follicular Carcinoma.- 79 Determinants of Prognosis of Follicular Thyroid Carcinoma.- PART VI. VARIANTS OF THYROID CANCER.- 80 Aggressive Variants of Papillary Thyroid Carcinoma and Poorly Differentiated Carcinoma.- 81 Miscellaneous and Unusual Tumors of the Thyroid Gland.- 82 Pathology of Miscellaneous and Unusual Tumors of the Thyroid Gland.- PART VII. UNDIFFERENTIATED TUMORS: MEDULLARY THYROID CARCINOMA.- 83 Clinical Aspects of Medullary Thyroid Carcinoma.- 84 Cytology and Pathology of Medullary Carcinoma.- 85 Medullary Carcinoma of the Thyroid: Surgical Management.- 86 Radionuclide Imaging of Medullary Carcinoma.- 87 PET/CT in Medullary Thyroid Cancer.- 88 Radiation Therapy in Medullary Cancer.- 89 Medullary Carcinoma of the Thyroid: Chemotherapy.- 90 A Comparison of the ATA, NCCN, ETA, and BTA Guidelines for the Management of Medullary Thyroid Cancer.- PART VIII. UNDIFFERENTIATED TUMORS: THYROID LYMPHOMA.- 91 Thyroid Lymphoma.- 92 Pathology of Lymphoma of the Thyroid.- 93 PET/CT in Lymphoma and Lymphoma of the Thyroid.- PART IX. UNDIFFERENTIATED TUMORS: ANAPLASTIC THYROID CANCER.- 94 Anaplastic Thyroid Carcinoma: Clinical Aspects.- 95 Surgical Management of Anaplastic Thyroid Carcinoma.- 96 Pathology of Anaplastic Carcinoma.- 97 PET/CT in Anaplastic Cancer of the Thyroid.- 98 Anaplastic Thyroid Cancer.- 99 Chemotherapy for Anaplastic Thyroid Cancer.- 100 Anaplastic Thyroid Carcinoma: Prognosis.- PART X. NEW FRONTIERS AND FUTURE DIRECTIONS.- 101 Advances in Radiation Therapy.- 102 New Approaches in Nuclear Medicine for Thyroid Cancer.- 103 124I in Differentiated Thyroid Cancer.- 104 Future Directions for Advanced Thyroid Cancer Therapy.- 105 Potential Approaches to Chemotherapy of Thyroid Cancer in the Future.- PART XI. Additional Resources.- 106 Prophylaxis against Radiation Exposure from Radioiodine.- 107 Low Iodine Diets.- 108 Appendix A: Books and Manuals.- 109 Appendix B: Additional Sources of Information: Support groups, Websites and additional information.- 110 Appendix C: Forms and Instructions for Patients Treated with Radioactivity.
Recenzii
“Thyroid Cancer: A Comprehensive Guide to Clinical Management was intended to meet the need of practicing physicians for up-to-date, clinically relevant information on the diagnosis and management of thyroid cancer. Physicians treating thyroid cancer patients will find the text comprehensive, accurate, and invaluable. I highly recommend this book to any physician involved in the care of patients with thyroid cancer.” (E. Edmund Kim, Journal of Nuclear Medicine, Vol. 58 (3), March, 2017)
Notă biografică
Leonard Wartofsky, MD, MACP
Department of Medicine
Washington Hospital Center
Washington, DC, USA
Douglas Van Nostrand, MD, FACP, FACNM
Nuclear Medicine
Washington Hospital Center
Washington, DC, USA
Department of Medicine
Washington Hospital Center
Washington, DC, USA
Douglas Van Nostrand, MD, FACP, FACNM
Nuclear Medicine
Washington Hospital Center
Washington, DC, USA
Textul de pe ultima copertă
Thoroughly revised and extensively expanded, this encyclopedic, highly acclaimed title addresses all aspects of the etiology, pathogenesis, diagnosis, initial treatment and long-term management of all varieties of thyroid cancer. Expertly edited by Drs. Leonard Wartofsky and Douglas Van Nostrand, this gold standard reference is divided into 11 Parts: General Considerations on Thyroid Cancer; General Considerations on Nuclear Medicine; the Thyroid Nodule; Well-Differentiated Thyroid Cancer; Variants of Thyroid Cancer, Undifferentiated Tumors: Medullary Thyroid Carcinoma; Undifferentiated Tumors: Thyroid Lymphoma; Undifferentiated Tumors: Anaplastic Thyroid Cancer; New Frontiers and Future Directions; and Additional Resources. With exceptional breadth and depth, the book includes chapters dedicated to isotopes, isotope uptake and scanning procedures such as SPECT/CT, radioiodine ablation (with or without recombinant human TSH), stunning, dosimetry (with or without recombinant human TSH),Octreotide and FDG-PET scanning and other alternative imaging modalities. There is a valuable reference atlas of scan images and illustrations, and a scholarly summary of the side effects of radioiodine and how to avoid or minimize adverse effects of treatment. In addition to an updated section on ultrasonography of the thyroid gland, new sections have been added, including ones on ultrasonography of cervical lymph nodes and imaging for thyroid cancer employing computerized tomography (CT), positron emission tomography (PET) and magnetic resonance imaging (MRI). An indispensable reference source with chapters written by the field’s leading authoritative experts, Thyroid Cancer: A Comprehensive Guide to Clinical Management, Third Edition, will be of great interest to not only pathologists, endocrine surgeons, endocrinologists, nuclear medicine physicians, and oncologists but all clinicians with an interest in thyroid cancer.
Caracteristici
Comprehensive, definitive, gold-standard text in the field Expanded, with approximately 30 new chapters and fully updated references Written by a panel of world-class clinicians reviewing all aspects of thyroid cancer from pathogenesis to prognosis, including management and treatment Includes supplementary material: sn.pub/extras
Descriere
Descriere de la o altă ediție sau format:
are new to this edition. The authors provide not only the The second edition of Thyroid Cancer: A Comp- most current review of their respective areas, but also their hensive Guide to Clinical Management marks the pub- own recommendations and approach. The reader is fo- cation of a markedly updated and expanded volume that warned that in many cases these approaches, albeit rooted covers all aspects of the etiology, pathogenesis, diag- sis, initial treatment, and long-term management of all in available data, may be empiric rather than based varieties of thyroid cancer. Like the first edition, it will upon clear-cut results of well-controlled clinical t- als. Nevertheless, controversial issues are examined serve as a valuable reference source for pathologists, and evidence-based recommendations are presented endocrine surgeons, endocrinologists, nuclear medicine when available. physicians, and oncologists. However, the biggest There are updated chapters on our current state change is that the second edition is significantly enlarged and expanded to encompass important and extensive of knowledge of the molecular changes in thyroid treatments of more topics related to nuclear medicine. cancer, molecular markers, and how targeted the- pies are being developed. New therapeutic trials of Nuclear medicine physicians and procedures play a key redifferentiation agents to restore the sodium iodide role in the management of thyroid cancer patients and in symporter when lacking and more traditional che- retrospect, a comprehensive discussion of topics related therapies are discussed, with referral sources listed for to that field was somewhat lacking in the first edition.
are new to this edition. The authors provide not only the The second edition of Thyroid Cancer: A Comp- most current review of their respective areas, but also their hensive Guide to Clinical Management marks the pub- own recommendations and approach. The reader is fo- cation of a markedly updated and expanded volume that warned that in many cases these approaches, albeit rooted covers all aspects of the etiology, pathogenesis, diag- sis, initial treatment, and long-term management of all in available data, may be empiric rather than based varieties of thyroid cancer. Like the first edition, it will upon clear-cut results of well-controlled clinical t- als. Nevertheless, controversial issues are examined serve as a valuable reference source for pathologists, and evidence-based recommendations are presented endocrine surgeons, endocrinologists, nuclear medicine when available. physicians, and oncologists. However, the biggest There are updated chapters on our current state change is that the second edition is significantly enlarged and expanded to encompass important and extensive of knowledge of the molecular changes in thyroid treatments of more topics related to nuclear medicine. cancer, molecular markers, and how targeted the- pies are being developed. New therapeutic trials of Nuclear medicine physicians and procedures play a key redifferentiation agents to restore the sodium iodide role in the management of thyroid cancer patients and in symporter when lacking and more traditional che- retrospect, a comprehensive discussion of topics related therapies are discussed, with referral sources listed for to that field was somewhat lacking in the first edition.